TSS
RNAM

Two Sigma Securities’s Avidity Biosciences RNAM Stock Holding History

Two Sigma Securities’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-14,079
Closed -$127K – 3540
2023
Q4 		$127K Buy
+14,079
New +$94.1K ﹤0.01% 2490

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Two Sigma Securities's RNAM Position: Q1 2024 in Review

Two Sigma Securities sold out of Avidity Biosciences (RNAM) in Q1 2024, closing a stake of 14,079 shares — an estimated $127K sold.

Two Sigma Securities first reported a position in RNAM in Q4 2023 and held it in 1 quarter. The position peaked at $127K in Q4 2023. 158 funds tracked by Wall St. Rank hold RNAM as of Q1 2024.

  • Two Sigma Securities reported no remaining Avidity Biosciences position as of Q1 2024 after selling out during the quarter.
  • Two Sigma Securities sold 14,079 Avidity Biosciences shares in Q1 2024, an estimated $127K.
  • Two Sigma Securities first reported a position in Avidity Biosciences in Q4 2023 and held it in 1 quarter.
  • Two Sigma Securities's Avidity Biosciences position peaked at $127K in Q4 2023.
  • 158 funds tracked by Wall St. Rank held Avidity Biosciences as of Q1 2024.

Based on Two Sigma Securities's 13F filing for Q1 2024, filed 15 May 2024.